Kinaxis Announces Results of Voting at Annual Meeting of Shareholders
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain orchestration, received approval for all resolutions put forward to shareholders at today’s Annual Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated April 28, 2025 (the “Circular”).
1. Election of Directors
Shareholders voted to elect all seven directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed.
Name of Nominee | Total Number of Votes For | Percentage of Votes For | Total Number of Votes Against | Percentage of Votes Against |
Robert Courteau | 22,065,236 | 95.74% | 982,599 | 4.26% |
Gillian (Jill) Denham | 22,357,176 | 97.00% | 690,659 | 3.00% |
José Alberto Duarte | 22,430,093 | 97.32% | 617,742 | 2.68% |
Lynn Loewen | 22,702,703 | 98.50% | 345,163 | 1.50% |
Angel Mendez | 22,338,977 | 96.92% | 708,858 | 3.08% |
Pamela Passman | 22,394,586 | 97.17% | 653,249 | 2.83% |
Kelly Thomas | 22,562,248 | 97.89% | 485,588 | 2.11% |
2. Appointment of Auditors
Shareholders voted to approve the appointment of KPMG LLP as auditors for Kinaxis and hold office until the close of the next annual meeting of shareholders or until a successor is appointed.
Total Number of Votes For | Percentage of Votes For | Total Number of Votes Withheld | Percentage of Votes Withheld |
22,811,181 | 98.58% | 328,559 | 1.42% |
3. Advisory Vote on Approach to Executive Pay
Shareholders voted to accept the Company’s approach to executive compensation as described in the Circular.
Total Number of Votes For | Percentage of Votes For | Total Number of Votes Against | Percentage of Votes Against |
20,455,842 | 88.75% | 2,592,194 | 11.25% |
For further details on each of the above matters, please refer to the Circular available under Kinaxis’ profile on the System for Electronic Document Analysis and Retrieval (SEDAR+) at www.sedarplus.ca, or in the Financials section of the Company’s Investor Relations website.
Final voting results on all matters voted on at the AGM will be filed on SEDAR+ at www.sedarplus.com.
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™ combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
Source: Kinaxis Inc
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617983181/en/
Contacts
Media Relations
Matt Tatham | Kinaxis
mtatham@kinaxis.com
+1 917-446-7227
Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
+1 613-907-7613
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Americhem Aligns European Region Under Global Brand18.6.2025 10:00:00 EEST | Press release
Americhem Inc., a global leader in polymer solutions, has unified its European operations under the Americhem brand—streamlining customer experience and reinforcing alignment across global quality and manufacturing standards. “This move simplifies how we scale and serve,” said CEO John Richard. “One brand delivers clarity, consistency, and confidence.” The Denmark site supports Americhem’s healthcare strategy, producing ISO 13485 compounds for hearing aids, surgical tools, and drug delivery. Clean compounding developed in North America has been replicated, with expansion planned in Asia. Key focus areas also include fibers and building products, where material durability, color precision, and speed-to-market matter most. Local teams now operate fully within Americhem’s global systems. “Customers here get the same responsiveness and quality trusted across our global network,” said Barto DuPlessis, Vice President and General Manager of Europe. The shift also advances Americhem’s 2030 sus
Yokogawa Collaborates with Shell on Robotics and AI Technology for Plant Maintenance18.6.2025 09:00:00 EEST | Press release
Yokogawa Electric Corporation (TOKYO: 6841) announces that it has formalized a long-term agreement with Shell Global Solutions International B.V. (“Shell”) to integrate and further develop technologies for utilizing robots and drones in plant monitoring and maintenance. Under the agreement, Yokogawa will add an advanced machine vision tool called Operator Round by Exception (ORE), developed by Shell, into its own OpreX™ Robot Management Core. The enhanced software service will be made available by Yokogawa to customers in the energy, chemicals, and other industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617976629/en/ OpreX Robot Management Core ORE is a digital solution that uses machine vision and AI analytics to enable robots to autonomously perform a number of tasks in the operator round process, such as reading gauges and checking for leaks and machinery issues. It is the result of a two-year collaborative ef
Ververica Announces Partnership with Aiven - Empowering Leading Enterprises to Create Value from their Data in Real-Time18.6.2025 09:00:00 EEST | Press release
Ververica, the original creators of Apache Flink® and a leader in stream processing technology, today announced a new partnership with Aiven, the AI-ready open source cloud data platform. This partnership enables Aiven to provide Ververica’s Unified Streaming Data Platform to their customers, expanding access to enterprise-grade streaming data capabilities for data-driven businesses around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617806011/en/ Ververica Announces Partnership with Aiven - Empowering Leading Enterprises to Create Value from their Data in Real-Time Under the partnership, Aiven customers can now unlock enterprise-grade stream processing with Ververica’s powerful platform — allowing them to make decisions and take actions at speed with data from any source — plus expert support from the original creators of Apache Flink. “This partnership is about removing friction and delivering real business
ICD 2025: New data demonstrate Nemluvio ® ’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years18.6.2025 08:00:00 EEST | Press release
Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data show Nemluvio is well tolerated and associated with sustained and clinically meaningful improvements in symptoms including itch and skin lesions, during prolonged treatment up to two years.1 These new data will be presented as a late-breaking session at ICD, on Saturday, June 21, 2025 at 08:30 AM CET. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617336479/en/ “These promising data go even further in highlighting the extensive benefits of Nemluvio. As this treatment becomes available in more countries around the world, it’s highly encouraging to see its robust evidence base continue to expand and strengthen.” BALDO SCASSELLATI SFORZOLINI, M.D., PHD. GLOBAL HEAD OF RESEARCH & DEVELOPMENT GALDERMA Prurigo nodularis is a chronic, de
LabPMM ® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials18.6.2025 07:30:00 EEST | Press release
Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide. The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases,1 stable over time,2 and, if present in blood at allele
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom